Johirul Islam

Johirul Islam

Auto-generated profile, based on publicly available information

Johirul Islam

Department of Pharmacy, School of Pharmacy and Public Health Independent University, Bangladesh (IUB) Dhaka Bangladesh

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Scientifica
Verified
Journal Article
Open access
NSNawfal Hasan Siam
Nawfal Hasan Siam
NNNajibah Nasrin
Najibah Nasrin
SSSharmily Saiyara
Sharmily Saiyara
HSHridoy Saha
Hridoy Saha
DDDebashis Paul Deb
Debashis Paul Deb
JIJohirul Islam
Johirul Islam
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid deposition, tau hyperphosphorylation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and blood–brain barrier disruption, collectively leading to widespread cortical and subcortical atrophy. Current FDA‐approved pharmacotherapies, including acetylcholinesterase inhibitors and memantine, provide only modest symptomatic relief and fail to halt disease progression, underscoring the urgent need for alternative therapeutic approaches. Growing evidence highlights medicinal plants and their bioactive phytoconstituents as promising candidates for AD prevention and treatment because of their multitarget mechanisms, favorable safety profiles, and long history of traditional use. This review synthesizes extensive in vitro, in vivo, and clinical studies demonstrating the neuroprotective potential of plant extracts and isolated compounds that exert antioxidant, anti‐inflammatory, antiamyloidogenic, anti‐tau, cholinesterase‐inhibitory, and synaptic‐modulating effects. Key medicinal species, including Abelmoschus esculentus, Brassica oleracea, Cannabis sativa, Citrus reticulata, Lantana camara, Launaea taraxacifolia, Lawsonia inermis, Marrubium vulgare, Markhamia lutea, Persicaria minor, Pithecellobium dulce, Salvia aristata, Trigonella foenum-graecum , and Withania somnifera, show significant cognitive and neuroprotective benefits in experimental AD models. Phytochemicals such as sulforaphane, nobiletin, trigonelline, diosgenin, verbascoside, withaferin A, and withanolides strongly modulate the amyloid, tau, oxidative, and inflammatory pathways. Clinical trials further support the therapeutic potential of several plant‐derived interventions for mild cognitive impairment and AD‐related dementia. Collectively, these findings highlight medicinal plants and their active constituents as compelling complementary or translational strategies for AD management, warranting further mechanistic and clinical validation. This review aims to evaluate the neuroprotective potential of medicinal plants and their bioactive compounds in preventing and managing AD by summarizing evidence from in vitro, in vivo, and clinical studies.

26 August 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
NSNawfal Hasan Siam
Nawfal Hasan Siam
UMUmme Halima Mithila
Umme Halima Mithila
STSadia Alam Tisha
Sadia Alam Tisha
HSHridoy Saha
Hridoy Saha
AMAyesha Binte Mahbub
Ayesha Binte Mahbub
MCMd. Mazharul Islam Chowdhury
Md. Mazharul Islam Chowdhury
Background and Aims: Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, encompassing coronary artery disease, hypertension, heart failure, and cerebrovascular disorders. The global burden of CVD continues to rise, driven by complex interactions among endothelial dysfunction, oxidative stress, inflammation, genetic predisposition, and lifestyle‐related risk factors. This review aims to provide a comprehensive overview of the epidemiology, pathophysiology, risk factors, and emerging therapeutic approaches for CVD, highlighting recent advances in precision medicine and phytotherapy. Methods: A comprehensive literature search was conducted using PubMed, ScienceDirect, and Google Scholar databases. Keywords included “cardiovascular disease,” “Atherosclerosis,” “Pathophysiology,” “Risk Factors,” “Treatment,” “Hyperglycemia,” and “Hypertension.” Approximately 300 publications were initially identified. Following title, abstract, and full‐text screening, 156 relevant articles were selected for inclusion. About 85% of the reviewed literature was published between 2020 and 2025, while the remaining 15% originated from 2016 to 2019. Results: The review demonstrates a substantial increase in the global burden of CVDs, with prevalence nearly doubling between 1990 and 2019 and mortality continuing to rise worldwide. Atherosclerosis emerged as the primary pathological basis of ischemic cardiovascular disorders, driven by endothelial dysfunction, oxidative stress, inflammatory cytokines, and vascular remodeling. Major modifiable risk factors include hypertension, smoking, diabetes, dyslipidemia, obesity, unhealthy diet, alcohol consumption, and physical inactivity, while age, sex, and genetic susceptibility contribute to disease risk. Emerging therapeutic strategies such as PCSK9 inhibitors, dual SGLT1/2 inhibitors, siRNA‐based therapies, CRISPR/Cas9 genome editing, and anti‐inflammatory biologics show promising clinical outcomes. Additionally, medicinal plants including Astragalus membranaceus , Citrus bergamia , Hibiscus sabdariffa , and Olea europaea exhibit cardioprotective effects. Conclusion: CVD remains a significant global health challenge requiring multifaceted management strategies. The integration of conventional pharmacotherapy, precision medicine, gene‐based interventions, and evidence‐based phytotherapeutics offers promising opportunities to improve cardiovascular outcomes and reduce the growing global disease burden.